Document Detail

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.
MedLine Citation:
PMID:  21415239     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The association between antidiabetic medications and the prognosis of human prostate cancer has not been explored. This study examined the impact of these drugs on the outcomes of diabetic patients with prostate cancer to provide a basis for diabetes management strategy in these patients.
PATIENTS AND METHODS: Records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 July 1999 and 31 December 2008 were reviewed. The survival, cancer pathological grade, stage at the time of diagnosis, and antidiabetic pharmacotherapy of the patients were analyzed.
RESULTS: A total of 233 consecutive cases were analyzed. In Kaplan-Meier analysis, thiazolidinedione (log-rank, P = 0.005) and metformin (log-rank, P = 0.035) usage were significant predictors of improved overall survival, while insulin and insulin secretagogue usage were not significant predictors. Multivariate Cox regression analysis showed that thiazolidinedione {hazard ratio [HR] = 0.454 [95% confidence interval (CI) 0.213-0.965], P = 0.040} and metformin [HR = 0.550 (95% CI 0.315-0.960), P = 0.035] usage remained as significant predictors of favorable survival after controlling for variables including age, race, Gleason grade, and stage.
CONCLUSIONS: Thiazolidinediones and metformin appear to be associated with improved overall survival of diabetic prostate cancer patients. The choice of antidiabetic pharmacotherapy may influence overall survival of these patients.
X-X He; S M Tu; M-H Lee; S-C J Yeung
Related Documents :
24194639 - Bozepinib, a novel small antitumor agent, induces pkr-mediated apoptosis and synergizes...
10762659 - Inhibition of growth and stimulation of apoptosis by beta-sitosterol treatment of mda-m...
24923109 - Resveratrol modulates apoptosis in 5-fluorouracyl treated colon cancer cell lines.
18056989 - The 44-kda pim-1 kinase phosphorylates bcrp/abcg2 and thereby promotes its multimerizat...
23665799 - Synthesis and activity evaluation of tilorone analogs as potential anticancer agents.
25136839 - Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients.
23266919 - Economic evaluation of pediatric cancer treatment: a systematic literature review.
4063709 - Solitary renal hamartoma not associated with tuberous sclerosis: roles of ct and angiog...
2409039 - Who guidelines for the use of analgesics in cancer pain.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-03-17
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  22     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-22     Completed Date:  2012-03-16     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  2640-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Diabetes Mellitus, Type 2 / complications,  drug therapy*,  mortality
Hypoglycemic Agents / therapeutic use*
Kaplan-Meier Estimate
Metformin / therapeutic use*
Middle Aged
Multivariate Analysis
Neoplasm Grading
Proportional Hazards Models
Prostatic Neoplasms / complications,  drug therapy*,  mortality
Statistics, Nonparametric
Thiazolidinediones / therapeutic use*
Grant Support
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Thiazolidinediones; 9100L32L2N/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expert second-opinion pathology review of lymphoma in the era of the World Health Organization class...
Next Document:  Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply rel...